)

Cytosorbents (CTSO) investor relations material
Cytosorbents H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Technology and product overview
Blood purification platform removes toxins and harmful substances using a proprietary polymer bead technology, with two main products: CytoSorb and DrugSorb-ATR.
CytoSorb is CE-marked, used in over 70 countries, and has achieved record sales and high gross margins.
DrugSorb-ATR targets perioperative bleeding in cardiac surgery, with two FDA Breakthrough Device designations and ongoing regulatory discussions.
The technology addresses a $300 million market, potentially growing to over $1 billion, and is supported by 22 U.S. patents and $50 million in government grants.
CytoSorb targets a broader ICU patient base than dialysis, addressing critical illnesses driven by inflammation.
Clinical evidence and real-world data
CytoSorb controls massive inflammation in critical illnesses such as sepsis, trauma, and cardiac surgery, impacting up to 60% of ICU patients.
Registry and peer-reviewed studies show significant improvements in blood pressure, vascular leakage, lung function, and reduced mortality when used early and intensively.
A meta-analysis of 744 septic shock patients demonstrated reduced in-hospital and 28–30 day mortality with CytoSorb.
Real-world data from the COSMOS Registry and other studies support the effectiveness of CytoSorb in septic shock.
DrugSorb-ATR enables urgent cardiac surgery for patients on blood thinners, reducing severe bleeding and transfusion needs.
Regulatory and market updates
DrugSorb-ATR received FDA and Health Canada denials due to data deficiencies, but no safety issues were found; both agencies proposed paths forward for approval.
The company is actively engaging with regulators and has filed for reconsideration in Canada, focusing on addressing outstanding concerns.
DrugSorb-ATR is already indicated for use in Europe, with real-world data and awards supporting its impact.
The company remains committed to achieving North American approval and believes in the favorable benefit-risk profile of DrugSorb-ATR.
Next Cytosorbents earnings date

Next Cytosorbents earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage